Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its drug candidate HLX6018. This investigational compound is a GARP/TGF-β1 compound monoclonal antibody (mAb) that is being developed to treat fibrosis-related diseases.
The development of HLX6018 has thus far involved an investment of RMB 49.45 million from Fosun, reflecting the company’s commitment to advancing novel therapies for fibrotic conditions. Currently, there are no similar products approved globally, positioning HLX6018 as a potential first-in-class treatment for this indication.- Flcube.com
